Start here if you're new
what it is
Climb Bio develops drugs for immune diseases like lupus, ITP, membranous nephropathy, and IgA nephropathy.
how it gets paid
Last year Climb Bio made n/a in revenue. budoprutug was the main engine at $0M, or 50% of sales.
what just happened
Climb Bio posted a -$0.63 quarterly loss, and the company still has no sales here.
At a glance
B balance sheet — gets the job done, barely
-$0.46 fy2024 eps est
0.65 beta
~$336M market cap
small cap
xvary composite: 47/100 — below average
What they do
Climb Bio develops drugs for immune diseases like lupus, ITP, membranous nephropathy, and IgA nephropathy.
There is no real moat yet. You are buying 2 named programs and 17 employees, so the story is concentration, not scale. Budoprutug targets CD19-positive B cells, a kind of immune cell that helps make harmful antibodies. CLYM116 targets APRIL, a protein signal that helps some antibody-making cells survive. If one study misses, the edge goes with it.
How they make money
n/a
annual revenue
budoprutug
$0M
CLYM116
$0M
other R&D
$0M
The products that matter
develops autoimmune drug candidate
budoprutug
Phase 1/2 · backs a $336M thesis
it is the only clinical-stage asset on the page, which means one Phase 1/2 program is carrying the entire equity story right now.
only asset that matters
Key numbers
$336M
market cap
You are paying $336M for a pre-revenue pipeline. That is a lot of money for no sales.
$0
long debt
$0 of debt means no lender is waiting. That helps, but equity holders still fund the lab.
17
employees
Seventeen people is a tiny team. That keeps overhead low and makes execution easier to watch.
0.65
beta
A 0.65 beta means less market noise than the average stock. Your real risk is the pipeline.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for CLYM right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Climb Bio posted a -$0.63 quarterly loss, and the company still has no sales here.
EDGAR shows the latest quarter EPS at -$0.63. The business is still pre-revenue, so losses are the story.
$0M
revenue
-$0.63
eps
n/a
n/a
loss per share
The -$0.63 loss matters because there is no revenue cushion yet.
source: EDGAR SEC filing
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is budoprutug failing to justify a $336M market cap.
med
single-asset dependency
Budoprutug is the only clinical-stage asset on the page. If the program disappoints in Phase 1/2, there is no second product line waiting to absorb the damage.
impact: 100% of the current thesis rests on one drug candidate.
med
dilution and financing risk
No revenue means development gets funded by capital markets, not customers. The December 2025 RA Capital exchange agreement is a reminder that financing is part of the operating model here.
impact: new capital can keep the trial alive, but it can also spread the same value across more shares.
med
early-stage clinical timeline
Phase 1/2 is still early. Safety, dosing, and efficacy all need to line up before commercialization becomes a real conversation.
impact: delays extend cash burn, and weak data can make the next financing harder and more expensive.
You are underwriting one drug, zero revenue, and a $336M valuation. That is a binary setup, not a diversified business.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical
budoprutug Phase 1/2 data
This is the number that matters. Positive data can reprice a $336M company fast. Bad data can do the reverse just as fast.
timeline
next clinical update date
No specific readout date is provided in this snapshot. That absence matters because early-stage biotech timelines are the calendar.
financing
cash runway and new funding
Monitor whether the company needs more capital after the December 2025 RA Capital exchange agreement. In a pre-revenue biotech, funding is fuel.
street view
loss forecasts drifting wider or tighter
The current fiscal-year EPS forecast is -$1.57. Watch whether estimates improve as the program matures or get worse as spending rises.
Analyst rankings
risk profile
average
risk rank 3 — typical risk profile — neither especially safe nor risky.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity
institutional ownership data for CLYM is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$6
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive